Cadonilimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.

**Synonyms:** - AK 104 - AK-104 - AK104 - Anti-PD-1 x CTLA-4 Bispecific Antibody AK104 - Anti-PD-1/CTLA-4 Bispecific Antibody AK104 - Anti-PD1/Anti-CTLA4 Bispecific Antibody AK104 - CADONILIMAB - PD-1 x CTLA-4 Dual Checkpoint Inhibitor AK104